PRMT5 and neoplasm: PRMT5 activity suppresses anti-tumor immune responses by supporting tumor intrinsic mechanisms allowing immune evasion, Treg function, and repression of IFN-1 and MHCI pathways [93, 103], providing a rationale for combining PRMT5 inhibitors with ICT.